




UNIVERSIDAD  
DE PALERMO

## INTERNATIONAL CONGRESS

# "THE LONG JOURNEY INTO BRCA1/2 GENES GOES ON: THE EMERGING LANDSCAPE OF BRCA-RELATED TUMORS"



**MODALITY:** HYBRID

**DATE:** May 24th, 2023

**Duration:** 9:00 am to 12:00 am.

**Lima-Time.**



Free Registration: <https://forms.gle/noEx9KfhqgZXGsfY8>

**AUDIENCE:** DOCTORS, BIOLOGISTS, GENETICISTS,  
ONCOLOGISTS, PATHOLOGISTS, MASTOLOGISTS,  
PSYCHOLOGISTS, NURSES, STUDENTS.

**ATTENDANCE CERTIFICATES:**  
TWO ACADEMIC CREDITS.

# INTERNATIONAL CONGRESS

## "THE LONG JOURNEY INTO BRCA1/2 GENES GOES ON: THE EMERGING LANDSCAPE OF BRCA-RELATED TUMORS"

### DIRECTORS:

Prof. Dr. Viviana Bazan (Italy-UP).

Prof. Dr. Jhony A. De La Cruz-Vargas (Perú-URP).



### ORGANIZING SCIENTIFIC BOARD

- Prof. Antonio Russo (University of Palermo, Italy);
- Prof. Dr. Daniele Fanale (University of Palermo, Italy);
- Prof. Juan Lucio Iovanna (INSERM U1068, Aix-Marseille Université and Institut Paoli-Calmettes, Marseille, France);
- Dr. Aly Gallo (Universidad Ricardo Palma, Lima, Peru);
- Prof. Stefano Caruso (Université Paris-est Créteil, UPEC, Paris, France);
- Dr. Valeria Amodeo (Institute Of Cancer Research, London, UK).

### FACULTY

- Amodeo Valeria - Institute of Cancer Research, London, UK
- Bazan Viviana - University of Palermo, Italy
- Calderon Monica - Universidad Ricardo Palma, Lima, Peru
- Caruso Stefano - Université Paris-est Créteil, UPEC, Paris, France
- Chenet Stella - Universidad Ricardo Palma, Lima, Peru
- Corsini Lidia Rita - University of Palermo, Italy
- De La Cruz-Vargas Jhony A. - Universidad Ricardo Palma, Lima, Peru
- Fanale Daniele - University of Palermo, Italy
- Gomez Moreno Henry - Universidad Ricardo Palma, Lima, Peru
- Iovanna Juan Lucio - Aix-Marseille Université and Institut Paoli-Calmettes, Marseille, France
- Russo Antonio - University of Palermo, Italy
- Ugo Randazzo - University of Palermo, Italy

### SCIENTIFIC SECRETARIAT

- Chiara Brando (E-mail: [chiabra92@libero.it](mailto:chiabra92@libero.it)) - University of Palermo, Italy
- Manuel Vela Ruiz ([jose.vela@urp.edu.pe](mailto:jose.vela@urp.edu.pe)) - Universidad Ricardo Palma, Perú.

BRCA1  
BRCA2

## RATIONALE

The critical role of BRCA1 and BRCA2 genes was discovered for the first time in 1994 and 1995 in families with a high prevalence of breast and ovarian cancers. Pathogenic variants detected in these genes remain, to date, the primary inherited cause of breast and ovarian tumors, with an 85% lifetime risk for breast and a 20–40% risk for ovarian cancer. However, the research in the past two decades has brought great progress and change in the field of breast and ovarian cancer, screening, prevention, and treatment. The diffusion of high-throughput next-generation sequencing technologies has provided a deep insight into the molecular biology of these tumors and many other genes and proteins within the homologous recombination pathway have been evaluated. The development of poly(ADP-ribose) polymerase inhibitors (PARPi) has been a major advance in the treatment of ovarian tumors and several clinical and translational trials are ongoing to validate prognostic and predictive utility of germline and/or somatic pathogenic variants in BRCA1/2 or other genes associated with HRD as biomarkers in breast and ovarian cancer. More recent evidence has shown the presence of pathogenic variants in BRCA1/2 and other cancer susceptibility genes also in pancreatic and prostate cancer. This discovery increases the risk and contributes to the prevalence of these cancers not just in high-risk families but in the general population as well. That is how the long journey into BRCA genes goes on, and the emerging landscape of genetic testing and management of BRCA-mediated tumor phenotypes (and beyond) continues to evolve.

## PROGRAM OVERVIEW

This international congress is designed to educate researchers, scientists, students and health care providers in cancer genetics by presenting cutting-edge data from renowned researchers and clinicians. This congress will provide new information on progress in cancer screening and prevention, as well as ongoing work in targeted therapy for BRCA1/2 and other pathogenic variant carriers through a series of presentations and discussions about topic.

## PROGRAM OBJECTIVES

At the completion of this congress, attendees should be able to:

- Discuss about recent progress on the genetic epidemiology of BRCA1/2 and other homologous recombination deficiency (HRD) genes.
- Describe current issues associated with carrying a BRCA1/2 pathogenic variant.
- Review new approaches to screening and prevention of hereditary breast, ovarian, pancreatic and prostate cancer.
- Discuss on new advances in treatment for pathogenic variant carriers in BRCA1/2 and other known cancer susceptibility genes.

# Program

9:00-9:15 am Registration  
9:15-9:30 am Welcome

## Session I: Hereditary breast and ovarian cancers

Moderators: Prof. Dr. Viviana Bazan and Prof. Dr. Jhony A. De La Cruz-Vargas

9:30-9:50 am BRCA genetic testing and Oncogenetic Counselling  
PhD, MB. Daniele Fanale (UP)

9:50-10:10 am Management and treatment of BRCA-mutated Breast Cancer  
PhD. Henry Gomez Moreno (AUNA-URP)

10:10-10:30 am HRD-related genomic instability in Ovarian Cancer  
PhD. Antonio Russo (UP) - MD, Ugo Randazzo (UP)

10:30-10:40 am Discussion

## Session II: Hereditary pancreatic and prostate cancers

Moderators: Prof. Juan Lucio Iovanna, Prof. Stefano Caruso and Dr. Aly Gallo

10:40-11:00 am The role of BRCA testing in Pancreatic Cancer  
PhD. Lidia Rita Corsini (UP)

11:00-11:20 am The role of BRCA testing in Prostate Cancer  
Dr. Monica Calderon (INEN-URP)

11:20-11:30 am Discussion

## Session III: Impact of Pathogenic Variants in other genes beyond BRCA

Moderators: PhD. Stella Chenet, PhD, MB. Daniele Fanale and PhD, Valeria Amodio (London, UK)

11:30-11:50 am The prevention of hereditary cancers beyond BRCA  
Prof. Dr. Viviana Bazan (UP)

12:00 am Closure



Link para el Zoom del curso

<https://us02web.zoom.us/j/88467000920?pwd=aENCWWMxVExPaGNxcTRDQTdReHg2UT09>